The blockade of TNF-α has been linked with enhancement of hepatic damage markers and decrease in insulin resistance which supports the crucial role in the pathogenesis of MASLD (194). The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.